Alzamend Neuro, Inc. announced the sudden passing of director Lynne Fahey McGrath, M.P.H., Ph.D., on July 20, 2026. Dr. McGrath had served on the Board of Directors since the company's initial public offering in June 2021. Alzamend Neuro, Inc. is a biopharmaceutical company focused on the development of neurodegenerative disease treatments.